Intelligence · Clinical Pipeline
First People's Hospital Pipeline
All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.
- Programs
- 1,136
Quick answer
First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
prescribing anapproved drug, examination
The First People's Hospital of Lianyungang
Irritable Bowel Syndrome With Diarrhea
1 trial -
profound neuromuscular blockade
The First People's Hospital of Lianyungang
Profound Muscle Relaxation
1 trial -
quetiapine fumarate tablet (Seroquel)
The First People's Hospital of Lianyungang
Bipolar Disorder
1 trial -
rhGM-CSF group
The First People's Hospital of Lianyungang
Mycoses
1 trial -
rhTPO
The First People's Hospital of Lianyungang
Primary Immune Thrombocytopenia
1 trial -
rhTPO
The First People's Hospital of Lianyungang
Thrombocytopenia
1 trial -
rituximab combined with corticosteroids
The First People's Hospital of Lianyungang
Primary Membranous Nephropathy
1 trial -
ropivacaine
The First People's Hospital of Lianyungang
Injury of Upper Limb
1 trial -
semaglutide combined with metformin
The First People's Hospital of Lianyungang
Osteoporosis
1 trial -
sodium zirconium cyclic silicate
The First People's Hospital of Lianyungang
Potassium Imbalance
1 trial -
ticagrelor
The First People's Hospital of Lianyungang
Inflammation
1 trial -
18F-FDG
The First People's Hospital of Lianyungang
Tumor, Solid
1 trial -
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
89Zr-KN035
The First People's Hospital of Lianyungang
Solid Tumor, Adult
1 trial -
99mTc-H7ND SPECT/CT imaging performed
The First People's Hospital of Lianyungang
NSCLC
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
The First People's Hospital of Lianyungang
Anal Fistula
1 trial -
ASC09/ritonavir group
The First People's Hospital of Lianyungang
2019-nCoV
1 trial -
ATRA+Venetoclax+Azacitidine
The First People's Hospital of Lianyungang
AML, Adult
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Adjustment of Antiplatelet Drugs
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial -
Albuterol
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Amberen
The First People's Hospital of Lianyungang
Climacteric Syndrome
1 trial -
Ambrisentan
The First People's Hospital of Lianyungang
Pulmonary Arterial Hypertension
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
AntiPlatelet therapy
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Aspirin
The First People's Hospital of Lianyungang
Anterior Ischemic Optic Neuropathy
1 trial -
Atorvastatin
The First People's Hospital of Lianyungang
Contrast-induced Acute Kidney Injury
1 trial -
Atorvastatin 20 Mg Oral Tablet
The First People's Hospital of Lianyungang
Atherosclerotic Cardiovascular Disease
1 trial -
Atorvastatin Calcium 20Mg Tab
The First People's Hospital of Lianyungang
Hyperlipidemias
1 trial -
BCL regimen
The First People's Hospital of Lianyungang
Peripheral T-cell Lymphoma
1 trial -
BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
BRL-101
The First People's Hospital of Lianyungang
Sickle Cell Disease
1 trial -
Bactoblis
The First People's Hospital of Lianyungang
Oral Disease
1 trial -
Basic treatment
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Best medical management
The First People's Hospital of Lianyungang
Stroke, Ischemic
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Brain Glioma
1 trial -
Bifidobacterium
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
Bivalirudin
The First People's Hospital of Lianyungang
ST-segment Elevation Myocardial Infarction (STEMI)
1 trial -
Botulinum Toxin Type A Injection [Botox]
The First People's Hospital of Lianyungang
Rosacea
1 trial -
Breast MRI interpretation
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Breztri Aerosphere
The First People's Hospital of Lianyungang
Lung Cancer, Nonsmall Cell
1 trial -
Budesonide/formoterol
The First People's Hospital of Lianyungang
COPD Exacerbation
1 trial
Frequently asked questions
How many pipeline programs does First People's Hospital have?
1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs